Categories
Algorithms Journal of Breast Cancer

How to Treat Triple Negative Breast Cancer | Dr. Ruth O’Regan Chair & Dr. Anna Weiss

Discussing the management using the algorithm of Triple Negative Breast Cancer (TNBC) – with Dr. Ruth O’Regan Chair of medicine Charles A. Dewey Professor at the University of Rochester Wilmot Cancer Institute & Dr. Anna Weiss Associate Professor – Department of Surgery, Oncology Wilmot Cancer Institute.

Categories
2023 ASH

ASH 2023 Leukemia/MDS/Myelofibrosis Highlights – TRANSFORM-1, MANIFEST-2, SAVE, AUGMENT-101 with Dr. Uma Borate

In discussion with Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center, The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Borate:

– TRANSFORM-1: Ph III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, International, Study of Navitoclax in Combination with Ruxolitinib vs Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

– MANIFEST-2: Ph III, Randomized, Double-Blind Study, Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis

– SAVE: Phase I/II, Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in AML

– AUGMENT-101: Ph I/II, Revumenib Monotherapy in Patients with R/R KMT2Ar Acute Leukemias: Efficacy and Safety Results

Categories
2023 SABCS

SABCS 2023 HER2+ Breast Cancer Highlights – APHINITY Sub-analysis, KATHERINE update, HER2CLIMB-02

In discussion with Dr. Daniel G. Stover, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 3 important practice informing studies in HER2+ disease with Dr. Stover:

– APHINITY Sub-analysis: Benefit of Adj Pertuzumab and Trastuzumab According to ER and HER2 Expression

– KATHERINE Update: Phase III Study of Adjuvant TDM-1 vs Trastuzumab for Residual Invasive HER2-positive Early Breast Cancer After Neoadj Chemo: Final IDFS and Updated OS analysis

– HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and TDM1 for Previously Treated HER2-positive Metastatic Breast Cancer

Categories
2023 SABCS

SABCS 2023 Breast Cancer Highlights – NATALEE, MONARCH-3, INAVO120, TROPION-Breast01

In discussion with Dr. Hope Rugo, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Rugo:

– NATALEE Update – Ribociclib + Nonsteroidal AI as Adj Treatment in Patients with HR+/HER2− Early Breast Cancer: Final iDFS analysis

– MONARCH 3 – Final OS Results of Abemaciclib Plus a Nonsteroidal AI as First-line Therapy for HR+, HER2– Advanced Breast Cancer

– INAVO120 – Phase III Study of Inavolisib or Placebo in Combination with Palbociclib and Fulvestrant in Patients with PIK3CA-mut, HR+, HER2– Locally Adv/Metastatic Breast Cancer

– TROPION-Breast01 – Phase III Study of Dato-DXd vs Chemo for Patients with Previously Treated Inoperable/Metastatic HR+, HER2– Breast Cancer

Categories
2023 ASH

ASH 2023 CLL/Lymphoma Highlights – ALPINE, SEQUOIA, SWOG-S1826, POLARIX Update with Dr. Mazyar Shadman

In discussion with Dr. Mazyar Shadman from the Fred Hutch Cancer Center, covering the Chronic Lymphocytic Leukemia and Lymphoma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Shadman:
– ALPINE: Ph 3, Extended Follow-up Confirms Sustained Superior PFS of Zanubrutinib vs Ibrutinib for Treatment of R/R Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
– SEQUOIA: Ph 3, Broad Superiority of Zanubrutinib Over BR Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Treatment-Naive Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)
– SWOG S1826: Nivolumab-AVD Is Better Tolerated and Improves PFS Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma
– POLARIX Update: Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Categories
2023 ASH

ASH 2023 Multiple Myeloma Highlights – PERSEUS, IsKia, Bortezomib dosing, KarMMA-3 Update with Dr. Jens Hillengass

In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass:

– PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len + Dex (Dara-VRd) vs VRd Alone in Patients with NDMM Who Are Eligible for Autologous Stem Cell Transplantation (ASCT)

– IsKia – Ph 3 Randomized Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in NDMM

– Bortezomib Dosing – Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in NDMM

– KarMMA-3 Update – Idecabtagene Vicleucel (ide-cel) vs Standard Regimens in Patients with Triple-Class–Exposed (TCE) RRMM: Updated Analysis

Categories
2023 SABCS

SABCS 2023 Breast Cancer Highlights – NSABP B-51, IDEA Update, ICARO

In discussion with Dr. Eleonora Teplinsky, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Teplinsky:

– NSABP B-51 – Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node Negative After Neoadjuvant Chemotherapy

– IDEA Update – Five-year Outcomes of the IDEA trial of Endocrine Therapy Without Radiotherapy After Breast-Conserving Surgery for Postmenopausal Patients Aged 50-69 With Genomically-Selected Favorable Stage I Breast Cancer

– ICARO – Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated with Axillary Dissection or Nodal Radiation

– Keynote-522 Update – Event Free Survival with neoadjuvant and adjuvant pembrolizumab in TNBC

Categories
Algorithms Hematology

How to Treat Myelodysplastic Syndrome (MDS) with Dr. Amer Zeidan

In discussion with Dr. Amer Zeidan, covering how to treat myelodysplastic syndrome (MDS) in community settings. Dr. Zeidan is the director of early therapeutics research and associate professor of medicine at the Yale School of Medicine – Smilow Cancer Hospital. With Dr. Zeidan we covered MDS management in low-risk and high-risk patient population.

Categories
2023 ESMO

ESMO 2023 GI Cancer Highlights – Codebreak300, CABINET, GASTFOX

In discussion with Dr. Rachna Shroff, covering the ESMO 2023 GI Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Shroff:

– Codebreak300 – Sotorasib plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer

– CABINET – Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus

– GASTFOX – Evaluate FOLFOX With or Without Docetaxel (TFOX) as First Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma

Categories
2023

ESMO 2023 Lung Cancer – Chapter 2 Highlights – PAPILLON, MARIPOSA, MARIPOSA-2, LIBRETTO-431

In discussion with Dr. Alexander Spira, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Spira:

– PAPILLON – Amivantamab Plus Chemo in Advanced NSCLC with EGFR Exon 20 Insertions

– MARIPOSA – Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced NSCLC

– MARIPOSA-2 – Amivantamab Plus Chemo (with or without Lazertinib) vs Chemo in EGFR-mutated Advanced NSCLC After Progression on Osimertinib

– LIBRETTO-431 – First-line Selpercatinib or Chemo and Pembrolizumab in RET Fusion-Positive Advanced NSCLC

Subscribe Now

Document

Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology